INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer. Patients will be randomized in a 1:1 ratio to receive either SB27 or Keytruda 200 mg intravenously every 3 weeks concurrently with chemotherapy (pemetrexed 500 mg/m2 with vitamin supplementation intravenous (IV) infusion over 10 minutes every 3 weeks and carboplatin area under the curve [AUC] 5 IV infusion over 15-60 minutes every 3 weeks for the first 4 cycles). More information on this study is available at clinicaltrials.gov (NCT06348199).
“We are thrilled to announce the initiation of Phase 3 clinical trial for SB27, after our successful Phase 1 clinical trial initiation in February 2024,” said Ilsun Hong, Vice President, Product Evaluation Team Leader of Samsung Bioepis. “Based on our extensive clinical trial experience accumulated over the years, we will work closely with study investigators to ensure successful completion of the clinical trials for SB27.”
As of April 2024, Samsung Bioepis has eight biosimilars approved and seven available around the worldiii – SB4 (etanercept), SB2 (infliximab), SB5 (adalimumab), SB3 (trastuzumab), SB8 (bevacizumab), SB11 (ranibizumab), SB12 (eculizumab), and SB15 (aflibercept)iv – along with three biosimilar candidates in pipeline – SB16 (denosumab), SB17 (ustekinumab) and SB27 (pembrolizumab).v
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – LinkedIn, X.
i KEYTRUDA is a trademark of Merck Sharp & Dohme Corp.
ii The countries of recruitment include Bosnia and Herzegovina, Brazil, Georgia, Germany, India, Japan, Malaysia, Mexico, Philippines, Romania, Serbia, Spain, Thailand, and Turkey.
iii “Approval” and “Availability” signify regulatory approval/launch in one or more markets and do not necessarily indicate approval/launch in all markets worldwide.
iv SB15 (aflibercept) is approved in Korea by the Ministry of Food and Drug Safety (MFDS) and is not yet available in the market.
v In the United States, the Biologics License Application (BLA) for SB17 is under review by the U.S. Food and Drug Administration (FDA). In Europe, SB17 has been recommended for approval by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), having received positive CHMP opinion in February 2024.
MEDIA CONTACT Anna Nayun Kim, nayun86.kim@samsung.com Jane Chung, ejane.chung@samsung.com
source: Samsung Bioepis
【香港好去處】etnet全新頻道盛大推出！全港最齊盛事活動資訊盡在掌握！► 即睇
